[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0014524A - Subunit-optimized fusion proteins - Google Patents

Subunit-optimized fusion proteins

Info

Publication number
BR0014524A
BR0014524A BR0014524-6A BR0014524A BR0014524A BR 0014524 A BR0014524 A BR 0014524A BR 0014524 A BR0014524 A BR 0014524A BR 0014524 A BR0014524 A BR 0014524A
Authority
BR
Brazil
Prior art keywords
fusion proteins
subunit
optimized fusion
optimized
fusion protein
Prior art date
Application number
BR0014524-6A
Other languages
Portuguese (pt)
Inventor
Dan Pollock
Harry M Meade
Klaus Bosslet
Original Assignee
Genzyme Transgenics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Transgenics Corp filed Critical Genzyme Transgenics Corp
Publication of BR0014524A publication Critical patent/BR0014524A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: "PROTEìNAS DE FUSãO OTIMIZADAS COM SUBUNIDADE". Um método para a fabricação de uma proteína de fusão tendo: um primeiro membro fundido a um segundo membro onde os primeiro e segundo membros são escolhidos de modo que a proteína de fusão se agrupe em um complexo tendo um número de subunidades que otimiza a atividade da forma multimérica do segundo membro.Invention Patent: "SUBUNITY-OPTIMIZED FUSION PROTEINS". A method for making a fusion protein having: a first member fused to a second member where the first and second members are chosen so that the fusion protein is grouped into a complex having a number of subunits that optimizes the activity of the multimedia form of the second member.

BR0014524-6A 1999-09-17 2000-09-18 Subunit-optimized fusion proteins BR0014524A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39907999A 1999-09-17 1999-09-17
PCT/US2000/025558 WO2001019842A1 (en) 1999-09-17 2000-09-18 Subunit optimized fusion proteins

Publications (1)

Publication Number Publication Date
BR0014524A true BR0014524A (en) 2002-06-11

Family

ID=23578058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014524-6A BR0014524A (en) 1999-09-17 2000-09-18 Subunit-optimized fusion proteins

Country Status (14)

Country Link
EP (1) EP1237900A4 (en)
JP (1) JP2003509038A (en)
KR (1) KR20020039346A (en)
CN (1) CN1379782A (en)
AU (1) AU781462B2 (en)
BR (1) BR0014524A (en)
CA (1) CA2384766A1 (en)
HU (1) HUP0202702A2 (en)
IL (1) IL148549A0 (en)
MX (1) MXPA02002768A (en)
NO (1) NO20021244L (en)
NZ (1) NZ517774A (en)
RU (1) RU2002110116A (en)
WO (1) WO2001019842A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
AU2002365196C1 (en) 2001-07-19 2009-08-13 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
SG10201900003WA (en) * 2013-11-19 2019-02-27 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111748A0 (en) * 1993-12-03 1995-01-24 Zeneca Ltd Proteins
GB9406974D0 (en) * 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
US5959171A (en) * 1994-08-17 1999-09-28 Pharming B.V. Method for the production of biologically active polypeptides in a mammal's
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US6528699B1 (en) * 1997-02-25 2003-03-04 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
GB9708918D0 (en) * 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
EP1088084B1 (en) * 1998-06-15 2006-09-13 GTC Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion protein

Also Published As

Publication number Publication date
EP1237900A4 (en) 2005-08-03
KR20020039346A (en) 2002-05-25
WO2001019842A9 (en) 2002-11-14
NO20021244D0 (en) 2002-03-13
JP2003509038A (en) 2003-03-11
NZ517774A (en) 2005-01-28
EP1237900A1 (en) 2002-09-11
AU3883101A (en) 2001-04-17
MXPA02002768A (en) 2002-08-30
WO2001019842A1 (en) 2001-03-22
HUP0202702A2 (en) 2002-12-28
CA2384766A1 (en) 2001-03-22
AU781462B2 (en) 2005-05-26
RU2002110116A (en) 2004-03-10
CN1379782A (en) 2002-11-13
NO20021244L (en) 2002-05-13
IL148549A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
ATE339507T1 (en) ERYTHROPOIETIN ANALOG HUMAN SERUM-ALBUMIN FUSION PROTEIN
CO4810339A1 (en) NEW ARTIFICIAL STRUCTURES OF FUSION PROTEINS AND PREPARATION METHOD
CY1118991T1 (en) PHARMACEUTICAL FORM OF HUMAN ANTIBODIES FOR TREATMENT OF TNF-ALPHA DISORDERS
EE03424B1 (en) Method for the preparation of an allergy protein hydrolyzate formulation
FI974440A7 (en) Biphenyl-2-carboxylic acid tetrahydroisoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
BR9915548A (en) Interferon-beta fusion proteins and uses
PT952829E (en) PHENOFIBRATE PHARMACEUTICAL COMPOSITION WHICH PRESENTS HIGH BIODISPONIBILITY AND ITS PREPARATION
NO994757D0 (en) Procedure for Oral Administration of Proteins
PT1151004E (en) A PROCESS FOR THE PREPARATION OF IL-1RA A THERAPEUTICALLY ACTIVE PROTEIN FROM CORPORATE FLUIDS
PT1032555E (en) USED CYCLIC AMINO ACIDS AND DERIVATIVES AS PHARMACEUTICAL AGENTS
DE60139262D1 (en) SYSTEM FOR RECONSTRUCTING JOINT SURFACES OF MAMMALS
FI961621A7 (en) Protein: substituted tetra- and pentapeptide inhibitors of farnesyl transferase
DE69810612D1 (en) Pharmaceutical compositions with plasma proteins
EA199900331A1 (en) PREPARATION FROM COATED PARTICLES
NO993424L (en) Method for selective degradation of milk protein in the presence of other milk proteins
BR9509172A (en) Native complement pathway protein DNA sequence construction of conjugated dna use of a process protein to reduce complement pathway protein in a mammal and pharmaceutical formulation
DK1244472T3 (en) Particulate vitamin composition
DE68925275D1 (en) ENDOTOXIN BINDING PROTEIN AND THEIR USE
ATE380873T1 (en) PRENYLCYSTONE CARBOXYL METHYL TRANSFERASE, DNA CODING FOR THE SAME, AND A METHOD FOR SEARCHING FOR INHIBITORS
BR0014524A (en) Subunit-optimized fusion proteins
ES2117272T3 (en) ORAL PHARMACEUTICAL COMPOSITIONS INCLUDING A PROTEIN OR PEPTIDE, AN ANTIBODY AND POLYMERIC SPHERES.
DE69823225D1 (en) FUSION PROTEINS, CONSISTING OF PROTEIN INHIBITORS
DE69734586D1 (en) RETINOID METABOLIZING PROTEIN
BR9714376A (en) Somatostatin antagonists
SE8502540D0 (en) STABLE DENTIFRICE CONTAINING DEXTRANASE

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Free format text: GTC BIOTHERAPEUTICS, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008 POR TER SIDO INDEVIDO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009.